Briviact

Briviact

brivaracetam

Manufacturer:

UCB

Distributor:

Zuellig
Concise Prescribing Info
Contents
Brivaracetam
Indications/Uses
Adjunctive therapy in treating partial-onset seizures w/ or w/o secondary generalisation in adults & adolescents ≥16 yr w/ epilepsy.
Dosage/Direction for Use
Initially 50 or 100 mg/day in 2 equally divided doses, once in the morning & once in the evening. Dose may be adjusted between 50-200 mg/day if necessary. Inj/infusion may be given as an IV bolus or diluted in a compatible soln & administered as a 15-min IV infusion. Hepatic impairment Initially 50 mg/day. Max: 150 mg daily in 2 divided doses.
Administration
May be taken with or without food: Tab: Swallow whole w/ liqd. Oral soln: May be diluted in water or juice shortly before administration orally, via nasogastric or gastrostomy tube.
Contraindications
Hypersensitivity to brivaracetam or other pyrrolidone derivatives.
Special Precautions
Monitor patients for signs of suicidal ideation & behaviours. Minor or moderate influence on the ability to drive & use machines. Hepatic impairment. Not recommended in end-stage renal disease patients undergoing dialysis. Women of childbearing potential. Pregnancy & lactation. Elderly ≥65 yr. Childn <16 yr. FC tab: Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Oral soln: Rare hereditary problems of fructose intolerance. Contains methyl parahydroxybenzoate (E218). Oral soln & vial: Patients on controlled Na diet.
Adverse Reactions
Dizziness, somnolence. Flu; decreased appetite; depression, anxiety, insomnia, irritability; convulsion, vertigo; upper resp tract infections, cough; nausea, vomiting, constipation; fatigue.
Drug Interactions
Doubled effect of alcohol on psychomotor function, attention & memory. Possible increase in plasma conc w/ strong CYP2C19 inhibitors (eg, fluconazole, fluvoxamine). Decreased plasma conc w/ strong enzyme inducers (eg, rifampicin; carbamazepine, phenobarb, phenytoin; St. John's wort). May increase plasma conc of CYP2C19-metabolised products (eg, lansoprazole, omeprazole, diazepam); OAT3-transported medicinal products. May decrease plasma conc of CYP2B6-metabolised products (eg, efavirenz). Increased conc of carbamazepine epoxide.
MIMS Class
ATC Classification
N03AX23 - brivaracetam ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Briviact FC tab 50 mg
Packing/Price
56's
Form
Briviact oral soln 10 mg/mL
Packing/Price
(raspberry flavour) 300 mL x 1's
Form
Briviact soln for inj/infusion 50 mg/5 mL
Packing/Price
10 × 1's
Form
Briviact FC tab 100 mg
Packing/Price
56's
Form
Briviact FC tab 25 mg
Packing/Price
56's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in